Unable to hoodwink the people of Liberia about the risks of the Ebola vaccine trials, the snake oil salesmen are shuffling over to Guinea for a second shot.
“Now that Ebola is not the risk it was to Liberia several months ago, the trial is unlikely to continue according to the original plan. “It doesn’t make sense to expand the study in Liberia when there are fortunately no new infections occurring,” says Dr. H. Clifford Lane, the deputy director for clinical research and special projects at the National Institute of Allergy and Infectious Diseases. “We need to be sure we enroll a population that is still at risk for Ebola virus infection so we can show the protective effect of either or both of the vaccines,” writes Time.
In spite of a significant cash inducement to entrap impoverished locals, few in Liberia were tempted to put their health on…
View original post 132 more words